BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31015127)

  • 1. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer.
    Hiroshima Y; Fukumitsu N; Saito T; Numajiri H; Murofushi KN; Ohnishi K; Nonaka T; Ishikawa H; Okumura T; Sakurai H
    Radiother Oncol; 2019 Jul; 136():37-43. PubMed ID: 31015127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.
    Choi Y; Oh DY; Kim K; Chie EK; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Ha SW; Bang YJ
    Cancer Res Treat; 2016 Jul; 48(3):1045-55. PubMed ID: 26511805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis.
    Wang Z; Ren ZG; Ma NY; Zhao JD; Zhang Z; Ma XJ; Long J; Xu J; Jiang GL
    Radiat Oncol; 2015 Jan; 10():14. PubMed ID: 25575617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.
    Ogawa K; Ito Y; Hirokawa N; Shibuya K; Kokubo M; Ogo E; Shibuya H; Saito T; Onishi H; Karasawa K; Nemoto K; Nishimura Y;
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):559-65. PubMed ID: 22019243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients.
    Mattiucci GC; Boldrini L; Nardangeli A; D'Aviero A; Buwenge M; Cellini F; Deodato F; Dinapoli N; Frascino V; Macchia G; Morganti AG; Valentini V
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):661-667. PubMed ID: 33001271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer.
    Maemura K; Mataki Y; Kurahara H; Kawasaki Y; Iino S; Sakoda M; Ueno S; Arimura T; Higashi R; Yoshiura T; Shinchi H; Natsugoe S
    Pancreatology; 2017; 17(5):833-838. PubMed ID: 28778480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
    Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD
    JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study.
    Ogura Y; Terashima K; Nanno Y; Park S; Suga M; Takahashi D; Matsuo Y; Sulaiman NS; Tokumaru S; Okimoto T; Toyama H; Fukumoto T
    Radiat Oncol; 2022 Feb; 17(1):32. PubMed ID: 35144647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
    Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy.
    Kim YJ; Koh HK; Chie EK; Oh DY; Bang YJ; Nam EM; Kim K
    Int J Clin Oncol; 2017 Dec; 22(6):1069-1075. PubMed ID: 28477059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of gemcitabine for locally advanced pancreatic cancer: comparison with 5-fluorouracil-based chemoradiotherapy.
    Tada M; Arizumi T; Nakai Y; Sasaki T; Kogure H; Togawa O; Matsubara S; Tsujino T; Hirano K; Sasahira N; Isayama H; Kawabe T; Omata M
    Chemotherapy; 2008; 54(4):302-8. PubMed ID: 18689983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis.
    Terashima K; Demizu Y; Hashimoto N; Jin D; Mima M; Fujii O; Niwa Y; Takatori K; Kitajima N; Sirakawa S; Yonson K; Hishikawa Y; Abe M; Sasaki R; Sugimura K; Murakami M
    Radiother Oncol; 2012 Apr; 103(1):25-31. PubMed ID: 22300608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer.
    Kim TH; Lee WJ; Woo SM; Kim H; Oh ES; Lee JH; Han SS; Park SJ; Suh YG; Moon SH; Kim SS; Kim DY
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818783879. PubMed ID: 29962281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanced pancreatic cancer.
    Kang H; Chang JS; Oh TG; Chung MJ; Park JY; Park SW; Seong J; Song SY; Chung JB; Bang S
    Chemotherapy; 2014; 60(3):191-9. PubMed ID: 25824121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma.
    Ohkawa A; Mizumoto M; Ishikawa H; Abei M; Fukuda K; Hashimoto T; Sakae T; Tsuboi K; Okumura T; Sakurai H
    J Gastroenterol Hepatol; 2015 May; 30(5):957-63. PubMed ID: 25376272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment results of alternating chemoradiotherapy followed by proton beam therapy boost combined with intra-arterial infusion chemotherapy for stage III-IVB tongue cancer.
    Takayama K; Nakamura T; Takada A; Makita C; Suzuki M; Azami Y; Kato T; Hayashi Y; Ono T; Toyomasu Y; Hareyama M; Kikuchi Y; Daimon T; Mitsudo K; Tohnai I; Fuwa N
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):659-67. PubMed ID: 26521257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis.
    Chang JS; Chiu YF; Yu JC; Chen LT; Ch'ang HJ
    Cancer Res Treat; 2018 Apr; 50(2):562-574. PubMed ID: 28602054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer.
    Kelly P; Das P; Pinnix CC; Beddar S; Briere T; Pham M; Krishnan S; Delclos ME; Crane CH
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e143-9. PubMed ID: 23200173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrograde intra-arterial chemotherapy and daily concurrent proton beam therapy for recurrent oral cavity squamous cell carcinoma: Analysis of therapeutic results in 46 cases.
    Hayashi Y; Nakamura T; Mitsudo K; Yamaguchi H; Ono T; Azami Y; Takayama K; Suzuki M; Hatayama Y; Tsukiyama I; Hareyama M; Kikuchi Y; Fuwa N; Tohnai I
    Head Neck; 2016 Aug; 38(8):1145-51. PubMed ID: 27018982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.